IDT Australia Limited announced that the Therapeutic Goods Administration (TGA) has expanded the licensing conditions covering the Company's Aseptic Sterile Processing (ASP) facility. The updated license enables IDT to manufacture and supply Good Manufacturing Practice (GMP) injectable drugs for use in clinical trials in Australia and overseas. GMP is a set of principles and procedures that ensures the drugs are of high quality, as defined by the TGA.

This is an important milestone for IDT as the upgraded license allows the Company to expand its offering to the clinical trial industry to include injectable medicines. IDT is already licensed to produce GMP Specialised Orals and Active Pharmaceutical Ingredients (APIs) to the sector. The upgraded license further positions the Company to be a key partner for companies developing new therapies, particularly given the local and international shortage of ASP facilities that can manufacture advanced therapies.